On January 30, 2021, Amoy Diagnostics and AstraZeneca signed a strategic cooperation on HRD testing and companion diagnosis for ovarian cancer, hoping to jointly promote the development and post-marketing promotion of HRD companion diagnostic kits for ovarian cancer. This is another important milestone in cooperation between the two companies in the field of precision treatment of ovarian cancer after the BRCA mutation detection kit was successfully approved as an olaparib companion diagnostic reagent two years ago.

Relying on strong product research and development capabilities, Amoy Diagnostics was the first to obtain NMPA approval for the clinical application of BRCA mutation detection kits two years ago, and recently launched the first HRD testing service product. The product is optimized to conform to the SNP loci of Asian population, supporting rigorous and reliable HRD scoring and biocredential algorithm, which can accurately evaluate the patient genome scar status, and provide testing service support as the Laboratory Developed Test (LDT). Amoy Diagnostics's comprehensive product line fully meets the testing needs of patients at different levels.

Amoy Diagnostics has launched a strategic partnership with AstraZeneca to promote the BRCA mutation test kit to enable more ovarian cancer patients to benefit from compliant testing and standardized treatment. The signing of this strategic cooperation further expands the cooperation space between the two sides and will surely benefit more ovarian cancer patients with precision diagnosis and treatment.